Unleashing meaningful innovation through regulatory reform

19 October 2020

17:00-18:00 CET

Online

The first in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.

Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.

 

What effect do the shortcomings of current assessment processes have on the quality of innovation?

How do we resolve the conundrum of high prices and high uncertainty?

Our panelists discussed how regulatory and payment systems could be adapted to incentivise the timely generation of quality comparative data on the benefits and harms of new drugs and high-risk devices both before and after their market entry, profiting patients, clinicians, and healthcare systems.

Panellists

Beate Wieseler

Beate Wieseler

Head, Drug Assessment Department, Institute for Quality and Efficiency in Health Care (IQWiG)

Huseyin Naci

Huseyin Naci

Assistant Professor of Health Policy, London School of Economics and Political Science

Lydie Meheus PhD

Lydie Meheus PhD

Managing Director, Belgian Anticancer Fund

Andrea Cipriani MD PhD

Andrea Cipriani MD PhD

Professor of Psychiatry, University of Oxford

Moderated by

Yannis Natsis

Yannis Natsis

EPHA

#A2MDialogues

EPHA’s series of online discussions on key access to medicines (A2M) priorities brings together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.

Get involved !

Get involved !

Sign up here to receive our updates on European health policy and invitations to our events.

Subscribe now

You have Successfully Subscribed!

Share This